TBC
lls
  • Home
  • All Episodes
    • CAR T-cell Therapy
    • Leukemia
    • Lymphoma
    • Myelodysplastic Syndromes
    • Myeloma & Amyloidosis
    • Pediatric and AYA
    • General Treatment & Support
  • Subscribe by Email
  • About
  • FAQs
  • Visit LLS.org

Find us

Apple PodcastsGoogle PodcastsAmazon MusicAndroidiHeartRadioStitcherJioSaavnPodchaserPodcast Indexby EmailRSSMore Subscribe Options

Recent Episodes

Understanding and Treating LGBTQI+ Patients with Cancer

Chasity Burrows Walters, PhD, RN, Memorial Sloan Kettering Cancer Center, New York, NY

Chronic Myeloid Leukemia: What HCPs Need to Know

Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI

2022 ASH Annual Meeting: Highlights from the Perspective of a Conference Attendee

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY

Understanding Waldenström Macroglobulinemia

Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA

CAR T-cell Therapy in Review 2022: Updates in Treatment

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX

Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part II

Daphne Friedman, MD, Durham VA Health Care System, Durham, NC

Post navigation

1 2 3 4 5 6 … 12 Next »

Categories

  • All Episodes (68)
  • CAR T-cell Therapy (8)
  • Clinical Trials (3)
  • COVID-19 (7)
  • General Treatment & Support (16)
  • Genomics (3)
  • Health Equity (2)
  • Leukemia (15)
  • Lymphoma (8)
  • Minimal Residual Disease (MRD) (2)
  • Myelodysplastic Syndromes (2)
  • Myeloma & Amyloidosis (9)
  • Myeloproliferative Neoplasms (2)
  • Pediatric and AYA (9)
  • Rare Blood Cancers (3)
  • Transplantation (1)
  • Waldenström macroglobulinemia (2)

Meet Our Moderator

miller
Kenneth D. Miller, MD
Medical Oncologist and LLS Volunteer
For a complete listing of continuing education programs, visit www.LLS.org/CE     |      Disclaimer      |      Contact us with questions or to provide feedback
2020 Treating Blood Cancers Podcast Series – The Leukemia & Lymphoma Society.